← Back to Search

Peer Navigation for Psychiatric Disabilities (DRRRP-PHN Trial)

N/A

Recruiting

Led By Patrick W Corrigan, PsyD

Research Sponsored by Illinois Institute of Technology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 or older

Be older than 18 years old

Must not have

Currently receiving Assertive Community Treatment services

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 4 months, 8 months, 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether a peer navigator program can help adults with psychiatric disabilities improve their physical health and wellness.

Who is the study for?

This trial is for adults over 18 with serious mental illness who want to improve their physical health and wellness. They must be active members of Thresholds in the Chicago South Side area, willing to attend sessions but not already receiving peer support or Assertive Community Treatment services.

What is being tested?

The study tests a Peer Navigator Program (PNP) against usual integrated care. PNP uses peers with similar backgrounds and recovery experiences to help participants navigate healthcare services. The goal is better engagement, health, recovery, and quality of life.

What are the potential side effects?

Since this intervention involves peer navigation rather than medication, traditional side effects are not expected. However, there may be emotional or social impacts due to the nature of personal interactions within the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently getting support from a community mental health team.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 4 months, 8 months, 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 4 months, 8 months, 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4 months, 8 months, 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change from Baseline in 36-Item Short Form Health Survey (SF-36) Scores at Months 4, 8, and 12

Change from Baseline in Texas Christian University Health Form (TCU-HLTHFORM) Scores at Months 4, 8, and 12

Secondary study objectives

Change from Baseline in COVID-19 Social Distancing and Hygiene Scale Scores at Months 4, 8, and 12

Change from Baseline in Center for Epidemiologic Studies Depression Scale-Depression 10-item version (CES-D 10) Scores at Months 4, 8, and 12

Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scores at Months 4, 8, and 12

+7 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Peer Navigator Program (PNP)Experimental Treatment1 Intervention

Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include: * scheduling and attending healthcare appointments; * partnering with participant on tasks that arise from appointments; * health-related goal setting; and * taking action-steps toward health-related goals.

Group II: Treatment as Usual-Integrated Care (TAU-IC)Active Control1 Intervention

Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-half of research participants will be randomized to integrated care alone.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Peer Navigation

2016

N/A

~890

0 / 2Eligibility criteria met